{"id":898198,"date":"2025-10-21T11:10:34","date_gmt":"2025-10-21T15:10:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/"},"modified":"2025-10-21T11:10:34","modified_gmt":"2025-10-21T15:10:34","slug":"niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/","title":{"rendered":"Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025"},"content":{"rendered":"

<\/p>\n

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025<\/b><\/p>\n

LOS ANGELES–(BUSINESS WIRE<\/a>)–Niagen Bioscience, Inc.<\/a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Tuesday, November 4, 2025, at 4:30 p.m. ET to discuss its financial results for the third quarter 2025, which ended September 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, November 4, 2025.<\/p>\n

\nInvestor Conference Call:<\/p>\n

\nNiagen Bioscience management will host an investor conference call to discuss the third quarter 2025 financial results and provide a general business update on Tuesday, November 4, 2025, at 4:30 p.m. ET. Participants should call in at least 10 minutes before the call. The dial-in information is as follows:<\/p>\n

\nDate: Tuesday, November 4<\/p>\n

\nTime: 4:30 p.m. ET (1:30 p.m. PT)<\/p>\n

\nToll-free dial-in number: +1 888 596 4144<\/p>\n

\nConference ID: 8584242<\/p>\n

\nWebcast link: Niagen Bioscience Third Quarter 2025 Earnings Conference Call<\/a><\/p>\n

\nThe conference call will be broadcast live and available for replay via the investor relations section of the Company\u2019s website at www.niagenbioscience.com<\/a>.<\/p>\n

\nThe replay of the conference call will be available from 7:30 p.m. ET on Tuesday, November 4, 2025, to 11:59 p.m. ET on Tuesday, November 11, 2025. The replay dial-in information is as follows:<\/p>\n

\nToll-free replay number: +1 800 770 2030<\/p>\n

\nReplay ID: 8584242<\/p>\n

\nFor additional information on Niagen Bioscience, visit www.niagenbioscience.com<\/a>.<\/p>\n

About Niagen Bioscience:<\/b><\/p>\n

Niagen Bioscience, Inc.<\/a> (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience\u2122<\/sup> is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.<\/p>\n

\nThe Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.<\/p>\n

\nDistinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There\u2019s a better way to age.<\/p>\n

\nAt the heart of its clinically proven product portfolio is Niagen\u00ae<\/sup> (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company\u2019s consumer supplement, Tru Niagen\u00ae<\/sup>, the number one NAD+ boosting oral supplement in the United States\u2020<\/sup> (available at www.truniagen.com<\/a>), and Niagen Plus\u2122<\/sup>, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com<\/a>). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.<\/p>\n

\nNiagen Bioscience\u2019s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com<\/a>, where copies of press releases, news, and financial information are regularly published.<\/p>\n

\u2020<\/sup>Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1\/1\/2024 – 12\/31\/2024).<\/i><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20251021852088\/en\/<\/a><\/span><\/p>\n

Niagen Bioscience Media Contact:
\n<\/b>
Kendall Knysch, Senior Director of Media Relations & Partnerships
\n
310.405.5227
\n
kendall.knysch@niagenbio.com<\/a><\/p>\n

Niagen Bioscience Investor Relations Contact:
\n<\/b>
ICR, LLC
\n
Reed Anderson
\n
(646) 277-1260
\n
Stephanie Carrington
\n
(646) 277-1282
\n
niagenir@icrinc.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Vitamins\/Supplements Other Health Health Pharmaceutical<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 LOS ANGELES–(BUSINESS WIRE)–Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Tuesday, November 4, 2025, at 4:30 p.m. ET to discuss its financial results for the third quarter 2025, which ended September 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, November 4, 2025. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the third quarter 2025 financial results and provide a general business update … <\/p>\n

Continue reading “Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-898198","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNiagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 LOS ANGELES–(BUSINESS WIRE)–Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Tuesday, November 4, 2025, at 4:30 p.m. ET to discuss its financial results for the third quarter 2025, which ended September 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, November 4, 2025. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the third quarter 2025 financial results and provide a general business update … Continue reading "Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-21T15:10:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251021852088r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025\",\"datePublished\":\"2025-10-21T15:10:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/\"},\"wordCount\":586,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251021852088r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/\",\"name\":\"Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251021852088r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-10-21T15:10:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251021852088r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251021852088r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/","og_locale":"en_US","og_type":"article","og_title":"Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Market Newsdesk","og_description":"Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 LOS ANGELES–(BUSINESS WIRE)–Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Tuesday, November 4, 2025, at 4:30 p.m. ET to discuss its financial results for the third quarter 2025, which ended September 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, November 4, 2025. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the third quarter 2025 financial results and provide a general business update … Continue reading \"Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-21T15:10:34+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251021852088r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025","datePublished":"2025-10-21T15:10:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/"},"wordCount":586,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251021852088r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/","name":"Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251021852088r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-10-21T15:10:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251021852088r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251021852088r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=898198"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898198\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=898198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=898198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=898198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}